Shots:
- The biopharma industry is a multi-hundred-billion-dollar market, with a projected compound annual growth rate (CAGR) of 8.6%, the global biopharma market is expected to reach $1.41T by 2034. Eli Lilly and Co. ranked first with $65.17B, followed by Pfizer (61.19B) and AbbVie (61.16B), reflecting strong market concentration among large-cap innovators with diversified, high-value portfolios
- The analysis highlights a clear strategic shift toward high-growth therapeutic areas such as obesity, immunology, oncology, and rare diseases, fueled by blockbuster biologics and next-generation therapies. At the same time, companies are actively managing lifecycle challenges, including patent expiries, biosimilar competition, and portfolio transitions, while accelerating innovation through R&D investments and strategic deals.
- This Top 20 Biopharma Companies report provides a comprehensive view of the global biopharma landscape, highlighting leading companies, their financial performance, therapeutic focus areas, and recent strategic milestones, underscoring an industry increasingly driven by innovation, specialty therapies, and pipeline-led growth.
20. Regeneron Pharmaceuticals
Total Revenue: $14.34B
Founded Year: 1988
Total Employees: 15,400
Headquarters: New York, United States
Market Cap: $81.18B
Stock Exchange: NASDAQ
- Regeneron is a biotechnology company focused on discovering, developing, and commercializing innovative medicines, with a strong presence across immunology, oncology, ophthalmology, and rare diseases – areas where it continues to build both depth and scale.
- In 2025, the company reported a modest +0.99% YoY revenue growth, but the underlying story is more interesting: Dupixent ($17.8B) remains the clear growth engine, benefiting from expanding indications like COPD and broader patient reach, while the EYLEA franchise ($7.89B) continues to be a core contributor despite facing biosimilar pressure, supported by the transition to EYLEA HD, and Libtayo ($1.45B) is steadily gaining ground in oncology, particularly in lung cancer settings.
- More recently, in Mar’26, Regeneron saw another important milestone as Dupixent was approved in Japan for bullous pemphigoid.
19. CSL
Total Revenue: $15.4B
Founded Year: 1916
Total Employees: 29,900
Headquarters: Melbourne, Australia
Market Cap: $47.64B
Stock Exchange: ASX
- CSL is a global biotechnology company focused on developing and delivering plasma-derived therapies, vaccines, and specialty medicines, operating through key segments like CSL Behring, CSL Seqirus, and CSL Vifor – collectively addressing rare diseases, immunology, and infectious diseases.
- In 2025, the company reported a +1.16% YoY revenue growth, reflecting steady demand across its core plasma therapies and vaccines portfolio, with growth supported by increased plasma collection and improving global healthcare utilization trends.
- In Mar’26, CSL announced expansion of Illinois plasma therapy manufacturing facility enhancing production of plasma-derived therapies and albumin through advanced manufacturing capabilities
18. Teva Pharmaceuticals
Total Revenue: $17.25B
Founded Year: 1944
Total Employees: 32,000
Headquarters: Israel
Market Cap: $35.39B
Stock Exchange: NYSE
- Teva is a global pharmaceutical company known for its strong generics business alongside a growing portfolio of specialty medicines, with focus areas spanning central nervous system (CNS), respiratory, and oncology – balancing scale-driven generics with innovation-led specialty care.
- In 2025, the company reported a +4.31% YoY revenue growth, driven by its specialty segment momentum: Austedo ($2.21B) continues to be the key growth driver with strong uptake in movement disorders, Copaxone ($255M) continues its decline due to generic competition, while UZEDY ($191M) is gaining early traction as a long-acting injectable for schizophrenia, reflecting Teva’s push into differentiated CNS therapies.
- In Mar’26, Teva reported the US FDA biosimilar approval of Ponlimsi and acceptance of dual filings for its Xolair biosimilar candidate
17. Bayer
Total Revenue: $20.97B
Founded Year: 1863
Total Employees: 87,300
Headquarters: Leverkusen, Germany
Market Cap: $46.69B
Stock Exchange: ETR
- Bayer AG is a global life sciences company operating across pharmaceuticals, consumer health, and crop science, with its pharma division focused on areas like cardiovascular diseases, oncology, and ophthalmology – anchored by a mix of established blockbusters and newer growth assets.
- In 2025, the company reported a strong +11.05% YoY revenue growth, driven by a favorable product mix: Eylea ($3.65B) remained a key ophthalmology contributor despite competitive pressure, Nubeqa ($2.8B) emerged as a major growth driver with expanding adoption in prostate cancer, and Xarelto ($2.75B) continued to generate significant revenue, although facing gradual decline due to patent expiries and generic competition.
- In Mar’26, Bayer received EC approval for Kerendia (finerenone) in the EU to treat adults with symptomatic chronic heart failure with LVEF ≥40% (HFmrEF/HFpEF), expanding beyond its prior use in chronic kidney disease with type 2 diabetes.
16. Boehringer Ingelheim
Total Revenue: $26.74B
Founded Year: 1885
Total Employees: 54,300
Headquarters: Ingelheim, Germany
Market Cap: N/A
Stock Exchange: N/A
- Boehringer Ingelheim (BI) is a research-driven biopharma company operating across human pharmaceuticals and animal health, with a strong focus on cardiometabolic diseases, respiratory conditions, oncology, and immunology – anchored by a pipeline-led innovation strategy.
- In 2025, the company reported a strong +17.08% YoY revenue growth, largely driven by its core therapies: Jardiance ($10.33B) continues to lead as a blockbuster across diabetes, heart failure, and kidney disease, Ofev ($4.49B) remains a key growth driver in pulmonary fibrosis, while Trajenta ($1.72B) continues to contribute despite a mature lifecycle – highlighting a portfolio balancing high-growth and established assets.
- In Feb’26, Hernexeos (zongertinib) received FDA accelerated approval for advanced HER2-mutant NSCLC, based on a 76% objective response rate (N=72) in the Beamion LUNG-1 study, following Breakthrough Therapy Designation and prior approval in August 2025.
15. Takeda
Total Revenue: $28.57B
Founded Year: 1781
Total Employees: 47,500
Headquarters: Osaka, Japan
Market Cap: $57.38B
Stock Exchange: TYO
- Takeda is a global biopharma company focused on gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, and vaccines – driven by a science-led approach and a strong global footprint.
- In 2025, the company reported a -1.73% YoY (Jan-Dec’25) decline in revenue, reflecting portfolio dynamics: Entyvio ($6.14B) continues to anchor growth in inflammatory bowel disease, Takhzyro ($1.44B) shows steady momentum in rare diseases, while Gattex/Revestive ($913.56M) remains a solid contributor in gastrointestinal disorders – partially offset by generic pressure and loss of exclusivity in some legacy products.
- In Apr’26, Axsome has entered into an asset purchase agreement with Takeda for TAK-063 (balipodect), with an intention to develop it for treating schizophrenia & Tourette syndrome (P-III study-enabling activities for schizophrenia to begin in 2026)
14. Gilead Sciences
Total Revenue: $29.44B
Founded Year: 1987
Total Employees: 17,000
Headquarters: California, United States
Market Cap: $176.37B
Stock Exchange: NASDAQ
- Gilead is a global biopharma company focused on antivirals and specialty therapeutics, with leadership in HIV, oncology, and liver diseases – anchored by a strong antiviral franchise and an expanding oncology portfolio.
- In 2025, the company reported a +2.39% YoY growth in revenue, reflecting portfolio concentration: Biktarvy ($14.33B) continues to dominate the HIV segment with strong patient uptake, Descovy ($2.75B) remains a key contributor in both treatment and prevention, while Genvoya ($1.49B) continues its gradual decline as patients transition to newer regimens – highlighting a shift within its HIV portfolio.
- In Feb’26, Gilead has entered into a definitive agreement to acquire Arcellx, incl. anito-cel from their 2022 collaboration & Arcellx’s D-Domain CAR technology platform, for the implied equity value of $7.8B
13. Amgen
Total Revenue: $36.75B
Founded Year: 1980
Total Employees: 31,500
Headquarters: California, United States
Market Cap: $191.91B
Stock Exchange: NASDAQ
- Amgen is a leading biopharma company focused on innovative therapeutics across oncology, cardiovascular disease, inflammation, and bone health -leveraging biologics expertise and a growing pipeline of first- and best-in-class medicines.
- In 2025, the company delivered a strong +9.95% YoY revenue growth, supported by key brands: Prolia ($4.41B) continues to lead in bone health with sustained demand, Repatha ($3.01B) is gaining momentum driven by broader adoption in cardiovascular risk management, and Otezla ($2.26B) remains a steady contributor in inflammation despite increasing competition, highlighting a well-balanced growth portfolio.
- In Feb’26, The EC approved Amgen’s Uplizna (Inebilizumab) to treat generalized myasthenia gravis (gMG)
12. GSK
Total Revenue: $44.11B
Founded Year: 2000
Total Employees: 66,800
Headquarters: London, United Kingdom
Market Cap: $119.26B
Stock Exchange: LON
- GSK is a global biopharma company focused on vaccines, specialty medicines, and infectious diseases, with core therapeutic areas spanning respiratory, HIV, oncology, and immunology – anchored by a strong vaccines franchise and growing specialty pipeline.
- In 2025, the company delivered a solid +11.81% YoY revenue growth, largely driven by its vaccines portfolio: Shingrix ($4.85B) continues to lead with strong global uptake in shingles prevention, Bexsero ($1.61B) is gaining traction amid rising meningitis awareness and immunization programs, while Boostrix ($882.31M) remains a steady contributor in adult and adolescent vaccination, highlighting the strength of GSK’s vaccines-led growth strategy.
- In April’26, GSK reported the NMPA approval of Exdensur (Depemokimab) for severe asthma
11. Bristol-Myers Squibb (BMS)
Total Revenue: $48.19B
Founded Year: 1887
Total Employees: 32,500
Headquarters: New Jersey, United States
Market Cap: $121.42B
Stock Exchange: NYSE
- BMS is a global biopharma company focused on oncology, hematology, immunology, and cardiovascular diseases, with a strong portfolio of innovative therapies and a legacy of blockbuster drugs.
- In 2025, the company reported a slight 0.21% YoY revenue decline, reflecting portfolio dynamics: Eliquis ($14.44B) continues to anchor the business with strong demand in anticoagulation, Opdivo ($10.04B) remains a cornerstone in immuno-oncology across multiple indications, and Orencia ($3.7B) provides steady growth in immunology, partially offset by pressures from legacy products.
- In Mar’26, BMS’ Sotyktu (Deucravacitinib) wins FDA approval to treat adults with active psoriatic arthritis (PsA)
10. Novo Nordisk
Total Revenue: $48.67B
Founded Year: 1923
Total Employees: 69,200
Headquarters: Bagsvaerd, Denmark
Market Cap: $127.23B
Stock Exchange: CPH
- Novo Nordisk is a global healthcare company focused on diabetes, obesity, and rare diseases, with a strong leadership position in metabolic disorders driven by its GLP-1–based therapies and innovation-led pipeline.
- In 2025, the company delivered a standout +20.04% YoY revenue growth, powered by its obesity and diabetes franchise: Ozempic ($20B) continues to dominate with strong global demand in type 2 diabetes, Wegovy ($12.45B) is rapidly scaling as a leading obesity treatment, while Rybelsus ($3.47B) adds to the GLP-1 momentum as an oral option, highlighting Novo Nordisk’s clear leadership in the metabolic space.
- In Mar’26, Novo Nordisk’s Awiqli received the US FDA Approval for Type 2 Diabetes
9. Sanofi
Total Revenue: $51.31B
Founded Year: 1973
Total Employees: 74,800
Headquarters: Paris, France
Market Cap: $115.94B
Stock Exchange: EPA
- Sanofi is a global biopharma company focused on immunology, vaccines, rare diseases, and specialty care, with a strategic shift toward high-growth biologics and innovative therapies.
- In 2025, the company delivered a strong +19.93% YoY revenue growth, driven by its immunology leadership: Dupixent ($18.48B) continues to be the primary growth engine with expanding indications and global uptake, while Lantus ($2.03B) and Toujeo ($1.58B) remain important contributors in diabetes, albeit facing competitive and pricing pressures – reflecting a clear transition toward specialty medicines.
- In Mar’26, Regeneron and Sanofi reported MHLW’s approval of Dupixent to treat bullous pemphigoid
8. Novartis
Total Revenue: $54.53B
Founded Year: 1996
Total Employees: 75,300
Headquarters: Basel, Switzerland
Market Cap: $317.46B
Stock Exchange: SWX
- Novartis is a global medicines company focused on innovative pharmaceuticals, with core strengths across cardiovascular, immunology, neuroscience, and oncology, supported by a streamlined, innovation-driven portfolio.
- In 2025, the company reported a solid +8.37% YoY revenue growth, led by key growth brands: Entresto ($7.74B) continues to expand in heart failure treatment, Cosentyx ($6.66B) maintains strong demand in immunology across multiple indications, and Kisqali ($4.78B) is rapidly gaining traction in breast cancer, supported by expanding clinical data and adoption.
- In Mar’26, Novartis entered into an agreement to acquire Excellergy, incl. its asset Exl-111, strengthening Novartis immunology strategy in food allergy & other IgE-driven diseases
7. Merck & Co.
Total Revenue: $58.14B
Founded Year: 1891
Total Employees: 74,000
Headquarters: New Jersey, United States
Market Cap: $303.31B
Stock Exchange: NYSE
- Merck & Co. (Merck Sharp & Dohme or MSD outside US & Canada) is a global biopharma company focused on oncology, vaccines, infectious diseases, and cardiometabolic disorders, with a strong emphasis on innovative therapies and a leading position in immuno-oncology.
- In 2025, the company reported a modest +1.29% YoY revenue growth, shaped largely by its core portfolio: Keytruda ($31.68B) continues to dominate as one of the world’s top-selling oncology drugs with expanding indications, Gardasil/Gardasil 9 ($5.23B) remains a key growth driver in vaccines despite some demand fluctuations, and Januvia/Janumet ($2.54B) continues to decline as generic competition intensifies.
- In Feb’26, Merck has reorganized its Human Health division into two units: Oncology, and Specialty, Pharma & Infectious Diseases, to sharpen commercial execution & support a growing portfolio of launches across diverse therapeutic areas
6. AstraZeneca
Total Revenue: $58.73B
Founded Year: 1999
Total Employees: 96,100
Headquarters: Cambridgeshire, United Kingdom
Market Cap: $321.22B
Stock Exchange: LON
- AstraZeneca is a global biopharma company focused on oncology, cardiovascular, renal & metabolism, respiratory, and rare diseases, with a strong emphasis on science-led innovation and a growing oncology portfolio.
- In 2025, the company reported a solid +8.62% YoY revenue growth, supported by its oncology franchise: Tagrisso ($7.25B) continues to lead in lung cancer with strong global adoption, Imfinzi ($6.06B) is expanding across multiple cancer indications, and Calquence ($3.51B) is gaining traction in hematologic cancers – reflecting sustained momentum in its cancer portfolio.
- In Mar’26, AstraZeneca secured the EC approval of Imfinzi as a perioperative therapy for G/GEJ cancers
5. Roche
Total Revenue: $60.34B
Founded Year: 1896
Total Employees: 1,12,800
Headquarters: Basel, Switzerland
Market Cap: $328.89B
Stock Exchange: SWX
- Roche is a global healthcare leader spanning pharmaceuticals and diagnostics, with a strong focus on oncology, immunology, neuroscience, and ophthalmology, combining innovative drugs with advanced diagnostics to drive precision medicine.
- In 2025, the company delivered a strong +18.05% YoY revenue growth, supported by key growth drivers: Ocrevus ($8.87B) continues to lead in multiple sclerosis with sustained demand, Hemlibra ($6.01B) remains a cornerstone in hemophilia treatment, and Vabysmo ($5.19B) is rapidly scaling in ophthalmology, gaining share in retinal diseases.
- In Feb’26, The US FDA accepted Roche’s Giredestrant NDA for ESR1-mutated, ER-positive advanced breast cancer
4. Johnson & Johnson (JnJ)
Total Revenue: $60.4B
Founded Year: 1886
Total Employees: 1,38,200
Headquarters: New Jersey, United States
Market Cap: $581.22B
Stock Exchange: NYSE
- JnJ is a diversified healthcare company with a strong pharmaceuticals segment (Innovative Medicine) alongside medical devices, focusing on oncology, immunology, neuroscience, and cardiovascular diseases.
- In 2025, the company reported a +6.03% YoY revenue growth, supported by its key therapies: Darzalex ($14.35B) continues to lead in multiple myeloma with strong global demand, Stelara ($6.07B) remains a major contributor despite upcoming patent pressures, and Tremfya ($5.15B) is gaining traction in immunology with expanding use across indications.
- In Jan’26, JnJ received the US FDA’s Approval for Darzalex FASPRO regimen to treat newly diagnosed multiple myeloma (NDMM)
3. AbbVie
Total Revenue: $61.16B
Founded Year: 2013
Total Employees: 57,000
Headquarters: Illinois, United States
Market Cap: $375.69B
Stock Exchange: NYSE
- AbbVie is a global biopharma company focused on immunology, oncology, neuroscience, and aesthetics, with a strategy centered on advancing next-generation therapies while transitioning beyond its legacy blockbuster portfolio.
- In 2025, the company delivered a solid +8.56% YoY revenue growth, driven by its immunology portfolio: Skyrizi ($17.56B) continues to surge with strong uptake across psoriasis and IBD, Rinvoq ($8.3B) is expanding rapidly across multiple inflammatory conditions, while Humira ($4.54B) continues to decline following loss of exclusivity – marking a clear shift toward newer growth assets.
- In Jan’26, AbbVie entered PD-1×VEGF bispecific race with ~$5.6B deal for Remegen’s RC148
2. Pfizer
Total Revenue: $61.19B
Founded Year: 1849
Total Employees: 75,000
Headquarters: New York, United States
Market Cap: $154.84B
Stock Exchange: NYSE
- Pfizer is a global biopharma company focused on vaccines, oncology, cardiology, and rare diseases, with a broad portfolio spanning both innovative medicines and established therapies.
- In 2025, the company reported a -1.92% YoY revenue decline, reflecting portfolio shifts: Eliquis ($7.9B) remains a key anticoagulant franchise with steady demand, Prevnar family ($6.4B) continues to anchor its vaccines business despite some normalization, and Vyndaqel family ($6.38B) is rapidly growing in rare cardiomyopathy – helping offset declines in other segments.
- In Feb’26, Pfizer’s Braftovi regimen received US FDA full approval for metastatic colorectal cancer
1. Eli Lilly and Company (Lilly)
Total Revenue: $65.17B
Founded Year: 1876
Total Employees: 50,000
Headquarters: Indiana, United States
Market Cap: $902.48B
Stock Exchange: NYSE
- Lilly is a global biopharma company focused on diabetes, obesity, oncology, immunology, and neuroscience, with a strong emphasis on innovation in metabolic diseases and next-generation therapies.
- In 2025, the company delivered an exceptional +44.7% YoY revenue growth, driven by its metabolic franchise: Mounjaro ($22.96B) continues to see massive uptake in diabetes, Zepbound ($13.54B) is rapidly scaling in obesity, and Verzenio ($5.72B) remains a key contributor in breast cancer, reflecting strong momentum across both metabolic and oncology portfolios.
- In Apr’26, Eli Lilly reported the US FDA approval of Foundayo (Orforglipron) for weight loss
Criteria – The report is researched and created based on companies’ biopharma segment revenue, considering only the revenue reported for the period January to December 2025. For Japanese companies, or companies whose fiscal year does not end in December, the revenue has been calculated for the January to December period using their respective quarterly filings.
Source:
- Company Websites
- Press Releases
- Annual Reports
- Quarterly Reports
- Google Finance
- OANDA
Related Post: Top 20 Biopharma Companies of 2025
